reason report
anoth step forward evolv turnaround guidanc
bottom line reiter mp rate view elgx
still show mode execut improv
believ still like take sever qtr improv execut
fulli regain investor confid suspect result
allevi investor concern around busi stabil anoth
qtr slight revenue upsid reiter revenue guidanc
coupl gm/ op margin/ adj ep beat reiter
opex guidanc cash burn us ovat alto
approv delay disappoint earli vs prior view
op distribut agreement china increment posit
compani long term enter clear elgx
take step improv commerci organization/strategi still
expect share could volatil near-to-intermedi term
still wait-and-se execut stori like take month
see meaning revenue growth re-acceler
pt unchang
adj ep loss y/i cc came
slightli ahead our/ consensu estim in-lin
management guidanc revenue y/i outperform
think ou revenue y/i
cc under-perform slightli led smaller ou footprint result
exit smaller less profit market last yr product line us
global afx sale singl digit sequenti
better management expect global ovat sale saw sequenti
growth w/ double-digit sequenti growth us gm
beat consensu consensu
y/i due smaller us revenue lower lower overhead absorpt
due lower volum opex lower think
coupl gm upsid drove beat op margin adj ebitda
ex-sbc loss ahead us/consensu ultim
adj ep loss better estim consensu
elgx end cash balanc debt
balanc oper cash burn repres
medic suppli devic
sale sale
forecast
net debt total capit
year price history/av daili volume mil elgx
compani inform svb leerink llc research
revenu mm ep adjust item ep incorpor revers stock split enabl y/i compar
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
opex burn
re-affirmed management reiter confid us afx stabil
 revenue roughli equal cont
sequenti improv us ovat enabl busi return
growth management expect reinstat
nellix eu meaning impact revenue management
expect decis exit south korea impact
management expect revenu y/i
low-end guidanc usual season weaker qtr
revenue y/i y/i
respect total y/i y/i cc
model y/i consist management
busi strategi return above-market growth gm
expect rang unchang stabl gm
signific declin compani turn inventori
mfg varianc flow well opex still expect
rang model gm
opex adj ebitda/ep loss
oper cash burn off-set work capit
improv primarili cash burn exit
china distribut partnership posit view
elgx announc exclus distribut agreement
endovascular aneurysm seal eva product well
first negoti futur product china one largest
fastest-grow market management estim end-us
market opp ty eva evar grow hsd y/i elgx work
regulatori process begin sell
anticip subsequ commerci launch upon receipt
regulatori approv believ posit strateg decis
elgx enabl compet attract end market
leverag scale establish network/relationship
encourag qtr mark anoth qtr
slight revenue upsid us afx came better intern expect
remain track stabil us ovat revenue saw dd
elgx continu make progress increas presenc high-
volum center -- management indic secur new user
user came innovative/performance-bas
hospit compani receiv approv cheva
recruit pt complex abdomin aortic aneurysm aaa
center us ou commenc enrol
like least qtr us ovat alto approv delay
earli vs prior compani work process
submit respons fda regard submiss eu
approv still track enrol
expect complet end year vs end previous
enrol taken time trial site activ
enrol anoth three site final step activ
give line sight complet enrol year-end importantli
management anticip thay qtr delay enrol impact
approv timelin
rate endologix market perform pt elgx largest abdomin aortic
aneurysm aaa pure play hold market share posit us
ww aaa market per compani report us nellix approv potenti
event year delay vs prior expect think investor increasingli focus
turnaround exist platform afx ovat ceo onopchenko appoint
may initi busi re-set end aug /begin sept in-depth
evalu busi compani outlin three phase next year
analyst day aim improv commerci organization/strategi stabil
busi long-term goal return above-market growth profit came
away increas confid wheel come bu still wait-and-
see execut stori view near term believ price appreci prospect
next month tie compani abil execut guidanc remain
sidelin see potenti sourc drive upsid estim given elgx
bigger catalyst growth re-acceler weight take sever qtr
us believ investor get comfort compani abil execut
base valuat elgx group small-cap market cap med-tech compani
expect grow sale averag growth rate
elgx forecast assum y/i cc
growth y/i growth elgx current trade discount
group average sale vs sale vs
sale appli discount group multipl account execut risk
well chanc elgx may abl drive above-market growth nellix approv
expect pt base ev/sal multipl turn
discount group multipl elgx sale forecast use
cash posit debt account debt paydown
nellix repres key growth driver elgx compani cant secur fda approv
nellix approv delay out-year forecast could risk think afx/ov could
recaptur part unreal nellix revenu case anoth delay commerci
nellix us repres largest sale growth driver compani possibl
addit delay nellix could drive surgeon use elgx devic trial
risk limit portfolio breadth beyond aaa
elgx play sole aaa space compani abil servic institut
look consolid purchas across cardiolog servic line limit
hospit administr decid consolid purchas larger organ
elgx abil get shelf exist account penetr new account
could limit
elgx potenti acquisit target upsid risk price target
nellix opportun larger anticip manag demonstr
double-digit revenu growth ramp profit think elgx could repres
attract asset potenti acquir think acquir appetit differenti
small cap med-tech growth asset nellix appear fit bill sentiment around
name begin contempl takeout valuat could sourc upward pressur
vs price target
dollar million except ep
margin sale
compani report factset consensu svb leerink llc estim
dollar million except ep
margin sale
compani report svb leerink llc estim
dollar million except per-shar data
least
least
least
interest expens
dollar million except per-shar data
loss extinguish debt
chang fair valu cont consider
chang fair valu deriv liabil
dil share outstand incom
sale pro-forma
compani report svb leerink llc estim
dollar million except per-shar data
rest world row ex-europ
compani report svb leerink llc estim
